Publishing in July 2025 to coincide with the AACR Special Conference in Cancer Research: Artificial Intelligence and Machine Learning, the series will continue through December 2025! Technological ...

Maryland–based biotech NextCure acquired the rights to the CDH6-targeting antibody–drug conjugate (ADC) SIM0505 from Chinese company Simcere Zaiming for up to $745 million in combined upfront and ...

1State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, School of Life Sciences, Xiamen University, ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

1Department of Pediatrics III, University Children’s Hospital Essen, University of Duisburg-Essen, Essen, Germany. 2Department of Otorhinolaryngology & Head/Neck Surgery, University Hospital ...

1Hunan Key Laboratory of Skin Cancer and Psoriasis, Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China ...

1Key Laboratory of Dunhuang Medicine and Transformation at Provincial and Ministerial Level, Gansu University of Chinese Medicine, Lanzhou, China. 2Provincial-Level Key Laboratory for Molecular ...

Major Finding: PCSK9 regulates cholesterol uptake and controls the trajectory of metastasis to secondary organs in pancreatic ductal adenocarcinoma (PDAC). Concept: Cholesterol uptake supports ...

1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2Abramson Cancer Center and Abramson Family Cancer Research Institute, University of ...

1Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ...

Arvinas submitted a new drug application (NDA) to the FDA for vepdegestrant––its ER-targeting proteolysis targeting chimera (PROTAC) drug––for patients with ER-positive, HER2-negative, ESR1-mutated ...

Major Finding: Lipids derived from ascites are taken up by NK cells and drive NK cell dysfunction in ovarian cancer. Concept: Polar lipids such as phosphatidylcholine disrupt NK plasma membrane order ...